Kuramitsu K, Yoshida A
Second Department of Internal Medicine, Saitama Medical School, Japan.
Rheumatol Int. 1990;10(2):51-6. doi: 10.1007/BF02274783.
Plasma and synovial fluid levels and granulocytal elastase-alpha-1-protease inhibitor complex (EIC) in patients with rheumatoid arthritis (RA) were measured by enzyme-linked immunoassay and the results compared with those in patients with osteoarthrosis (OA). It was found that the plasma and synovial fluid levels of EIC in RA patients were higher than those in OA patients. There was a positive correlation between plasma EIC level in RA patients in Lansbury's index score of disease activity, as this tends to be higher when titer of RAHA in the plasma is high. The level of EIC in the synovial fluids correlated positively with granulocyte count and alpha-1-protease inhibitor (alpha-1-PI) level, and this, too, tends to be higher when titer of RAHA in synovial fluid is high. The results suggested that the level of EIC in the plasma or synovial fluids can be a good marker for the systemic or localized activation of the granulocytes and that IgM rheumatoid factor (IgMRF) is involved in the mechanism of the release of elastase.
采用酶联免疫吸附测定法检测类风湿关节炎（RA）患者血浆和滑液中粒细胞弹性蛋白酶-α1-蛋白酶抑制剂复合物（EIC）的水平，并将结果与骨关节炎（OA）患者进行比较。结果发现，RA患者血浆和滑液中EIC水平高于OA患者。RA患者血浆EIC水平与兰斯伯里疾病活动指数评分呈正相关，因为当血浆中类风湿关节炎血凝素（RAHA）滴度较高时，该评分往往也较高。滑液中EIC水平与粒细胞计数和α1-蛋白酶抑制剂（α1-PI）水平呈正相关，当滑液中RAHA滴度较高时，该水平也往往较高。结果表明，血浆或滑液中EIC水平可作为粒细胞全身或局部活化的良好标志物，且IgM类风湿因子（IgMRF）参与弹性蛋白酶释放机制。
